Literature DB >> 19775993

Anti-angiogenic therapy in ovarian cancer: a great expectation to be confirmed.

Antonio González Martín.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19775993     DOI： 10.1007/s12094-009-0404-0

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN： 1699-048X            Impact factor:   3.405


× No keyword cloud information.
  8 in total

1.  Intraperitoneal chemotherapy for optimally debulked advanced ovarian cancer: a new standard in patient care?

Authors:  A González Martín
Journal:  Clin Transl Oncol       Date:  2007-07       Impact factor: 3.405

Review 2.  Current status of anti-angiogenic agents in the treatment of ovarian carcinoma.

Authors:  Alfonso Sánchez-Muñoz; Elisabeth Pérez-Ruiz; César Mendiola Fernández; Emilio Alba Conejo; Antonio González-Martín
Journal:  Clin Transl Oncol       Date:  2009-09       Impact factor: 3.405

Review 3.  Angiogenesis and ovarian cancer.

Authors:  César Gómez-Raposo; Marta Mendiola; Jorge Barriuso; Enrique Casado; David Hardisson; Andrés Redondo
Journal:  Clin Transl Oncol       Date:  2009-09       Impact factor: 3.405

4.  Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.

Authors:  Stephen A Cannistra; Ursula A Matulonis; Richard T Penson; Julie Hambleton; Jakob Dupont; Howard Mackey; Jeffrey Douglas; Robert A Burger; Deborah Armstrong; Robert Wenham; William McGuire
Journal:  J Clin Oncol       Date:  2007-11-20       Impact factor: 44.544

5.  Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.

Authors:  Robert A Burger; Michael W Sill; Bradley J Monk; Benjamin E Greer; Joel I Sorosky
Journal:  J Clin Oncol       Date:  2007-11-20       Impact factor: 44.544

6.  Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.

Authors:  Michael A Bookman; Mark F Brady; William P McGuire; Peter G Harper; David S Alberts; Michael Friedlander; Nicoletta Colombo; Jeffrey M Fowler; Peter A Argenta; Koen De Geest; David G Mutch; Robert A Burger; Ann Marie Swart; Edward L Trimble; Chrisann Accario-Winslow; Lawrence M Roth
Journal:  J Clin Oncol       Date:  2009-02-17       Impact factor: 44.544

7.  Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening.

Authors:  Fiona Simpkins; Jerome L Belinson; Peter G Rose
Journal:  Gynecol Oncol       Date:  2007-07-23       Impact factor: 5.482

8.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702
  8 in total
  2 in total

Review 1.  Epithelial ovarian carcinoma: current evidences and future perspectives in the first-line setting.

Authors:  Antonio González-Martín; Gemma Toledo; Luis Chiva
Journal:  Clin Transl Oncol       Date:  2010-06       Impact factor: 3.405

2.  Effect of Mad2 on paclitaxel-induced cell death in ovarian cancer cells.

Authors:  Xing Hao; Zhigang Zhou; Shuangmei Ye; Ting Zhou; Yunping Lu; Ding Ma; Shixuan Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-11-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.